title: Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
abstract: Liraglutide (Victoza®) is a subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and used as an adjunct to diet and exercise in the treatment of adults with type 2 diabetes mellitus. This article reviews the clinical efficacy and tolerability of liraglutide in adults with type 2 diabetes, and provides a summary of its pharmacological properties. Recently published pharmacoeconomic studies of liraglutide are also reviewed. Administered subcutaneously, liraglutide (usually 1.2 or 1.8 mg once daily) generally produced greater improvements in glycaemic control than active comparators or placebo when administered as monotherapy or in combination with one or two oral antidiabetic drugs (OADs) to adults with type 2 diabetes in numerous randomized, controlled phase III trials. These included six trials in the LEAD trial programme that was designed to evaluate the efficacy and safety of liraglutide across a continuum of antihyperglycaemic management for patients with type 2 diabetes. Liraglutide was generally well tolerated, with a low risk of hypoglycaemia evident, in the phase III trials. The most common adverse events were gastrointestinal and included nausea and diarrhoea; most events were mild to moderate in severity and decreased in incidence over time. In conclusion, liraglutide has an important place in the management of adults with type 2 diabetes across a continuum of care. As well as providing effective glycaemic control, liraglutide improves pancreatic β-cell function and leads to bodyweight loss, thereby addressing some of the unmet needs of patients treated with traditional OADs.
authors.affiliation: Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Perry
mesh_terms: D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000069450:Liraglutide
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
references.citation: Diabetes Care. 2004 May;27(5):1047-53
references.pmid: 15111519
references.citation: Diabetes Care. 2009 Jan;32(1):193-203
references.pmid: 18945920
references.citation: Adv Ther. 2011 Mar;28(3):213-26
references.pmid: 21340616
references.citation: Endocrinology. 2010 Apr;151(4):1473-86
references.pmid: 20203154
references.citation: Int J Clin Pharmacol Ther. 2008 Jun;46(6):273-9
references.pmid: 18541123
references.citation: Pancreas. 2007 Nov;35(4):302-7
references.pmid: 18090234
references.citation: Diabetes. 2009 Apr;58(4):975-83
references.pmid: 19151200
references.citation: Diabetes Obes Metab. 2011 Jan;13(1):75-80
references.pmid: 21114606
references.citation: Diabet Med. 2008 Feb;25(2):152-6
references.pmid: 18201212
references.citation: Diabetes. 2002 Feb;51(2):424-9
references.pmid: 11812750
references.citation: Cardiovasc Diabetol. 2009 Feb 26;8:12
references.pmid: 19245711
references.citation: Lancet. 2009 Feb 7;373(9662):473-81
references.pmid: 18819705
references.citation: Diabetes Res Clin Pract. 2008 Aug;81(2):161-8
references.pmid: 18495285
references.citation: Pancreas. 2006 Nov;33(4):323-30
references.pmid: 17079934
references.citation: Drugs. 2007;67(6):935-54
references.pmid: 17428109
references.citation: Diabetes Care. 2004 Jun;27(6):1335-42
references.pmid: 15161785
references.citation: Diabetes Care. 2009 Jan;32 Suppl 1:S13-61
references.pmid: 19118286
references.citation: Diabetologia. 2009 Oct;52(10):2046-55
references.pmid: 19688338
references.citation: Adv Ther. 2011 Aug;28(8):650-60
references.pmid: 21792552
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: Can J Diabetes. 2009;33(3):209-10
references.pmid: 25998594
references.citation: J Clin Endocrinol Metab. 2011 Mar;96(3):853-60
references.pmid: 21209033
references.citation: Pharmacology. 2010;86(1):44-57
references.pmid: 20616619
references.citation: Diabet Med. 2011 Mar;28(3):333-7
references.pmid: 21309842
references.citation: Postgrad Med. 2009 May;121(3):5-15
references.pmid: 19491535
references.citation: Diabetes Care. 2002 Aug;25(8):1398-404
references.pmid: 12145241
references.citation: Br J Clin Pharmacol. 2010 Dec;70(6):807-14
references.pmid: 21175436
references.citation: Obesity (Silver Spring). 2007 Jul;15(7):1710-6
references.pmid: 17636089
references.citation: Diabetes Obes Metab. 2010 Jul;12(7):604-12
references.pmid: 20590735
references.citation: Endocr Pract. 2011 May-Jun;17(3):345-55
references.pmid: 21700561
references.citation: Diabet Med. 2009 Mar;26(3):268-78
references.pmid: 19317822
references.citation: Diabetes Obes Metab. 2009 Dec;11 Suppl 3:11-8
references.pmid: 19878257
references.citation: Am J Manag Care. 2010 Aug;16(7 Suppl):S187-94
references.pmid: 20809667
references.citation: J Clin Endocrinol Metab. 2011 Jun;96(6):1695-702
references.pmid: 21450987
references.citation: Lancet. 2010 Apr 24;375(9724):1447-56
references.pmid: 20417856
references.citation: J Clin Pharmacol. 2011 Jun;51(6):951-5
references.pmid: 20671294
references.citation: Diabetes Care. 2004 Aug;27(8):1915-21
references.pmid: 15277417
references.citation: Pharmacotherapy. 2006 Mar;26(3):360-74
references.pmid: 16503716
references.citation: Diabetes Obes Metab. 2010 Apr;12(4):341-7
references.pmid: 20380655
references.citation: J Med Chem. 2000 May 4;43(9):1664-9
references.pmid: 10794683
references.citation: Pancreas. 2006 Nov;33(4):336-44
references.pmid: 17079936
references.citation: Diabetes Obes Metab. 2009 Dec;11(12):1163-72
references.pmid: 19930006
references.citation: Clin Ther. 2011 Nov;33(11):1698-712
references.pmid: 22018679
references.citation: Diabetes Care. 2009 Jan;32(1):84-90
references.pmid: 18931095
references.citation: Diabetes Care. 2010 Jun;33(6):1300-3
references.pmid: 20332351
references.citation: Diabet Med. 2008 Sep;25(9):1129-31
references.pmid: 19183322
references.citation: Diabet Med. 2006 Jun;23(6):579-93
references.pmid: 16759299
references.citation: Diabetes Obes Metab. 2011 Jan;13(1):81-8
references.pmid: 21114607
references.citation: Lancet. 2009 May 23;373(9677):1765-72
references.pmid: 19465231
references.citation: Clin Ther. 2010 Sep;32(10):1756-67
references.pmid: 21194600
references.citation: J Diabetes Investig. 2011 Aug 2;2(4):280-6
references.pmid: 24843499
references.citation: Curr Med Res Opin. 2010 May;26(5):1013-22
references.pmid: 20199137
references.citation: Diabetes Care. 2007 Aug;30(8):2032-3
references.pmid: 17468345
references.citation: Endocr Pract. 2007 May-Jun;13 Suppl 1:1-68
references.pmid: 17613449
references.citation: Diabetologia. 2002 Feb;45(2):195-202
references.pmid: 11935150
references.citation: Drugs. 2009 Oct 1;69(14):1985-2004
references.pmid: 19747013
references.citation: Lancet. 2009 Nov 7;374(9701):1606-16
references.pmid: 19853906
references.citation: Lancet. 2009 Jul 4;374(9683):39-47
references.pmid: 19515413
references.citation: Drugs. 2011 Sep 10;71(13):1675-88
references.pmid: 21902291
references.citation: Prim Care Diabetes. 2010 Jul;4(2):113-7
references.pmid: 20444662
references.citation: Curr Med Res Opin. 2011 May;27(5):897-906
references.pmid: 21348806
references.citation: Diabetes Care. 2007 Jun;30(6):1608-10
references.pmid: 17372153
references.citation: J Diabetes Investig. 2011 Nov 30;2(6):441-7
references.pmid: 24843528
references.citation: Diabetes Obes Metab. 2011 Apr;13(4):348-56
references.pmid: 21205128
references.citation: Diabet Med. 2005 Aug;22(8):1016-23
references.pmid: 16026367
references.citation: Int J Clin Pract. 2011 Apr;65(4):397-407
references.pmid: 21355967
references.citation: Diabetes Care. 2009 Jul;32(7):1224-30
references.pmid: 19289857
references.citation: Diabetes. 2007 Jan;56(1):8-15
references.pmid: 17192459
references.citation: Br J Clin Pharmacol. 2009 Dec;68(6):898-905
references.pmid: 20002084
references.citation: Diabetes Care. 2009 May;32(5):834-8
references.pmid: 19208917
references.citation: J Clin Pharmacol. 2010 Aug;50(8):886-94
references.pmid: 20133507
references.citation: Diabetes. 2004 May;53(5):1187-94
references.pmid: 15111485
references.citation: Int J Clin Pract. 2010 Jan;64(2):267-76
references.pmid: 19925617
references.citation: Biochem Biophys Res Commun. 2005 May 6;330(2):577-84
references.pmid: 15796922
references.citation: J Clin Pharmacol. 2009 Nov;49(11):1353-62
references.pmid: 19737980
references.citation: Diabetes. 2003 Jul;52(7):1786-91
references.pmid: 12829647
references.citation: Endocr Pract. 2009 Sep-Oct;15(6):540-59
references.pmid: 19858063
references.citation: Pharmacotherapy. 2009 Nov;29(11):1280-8
references.pmid: 19873688